Risk factors
CRISPR Therapeutics (CRSP) risk factors
Item 1A of every CRISPR Therapeutics AG 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors102 risks18 new14 dropped29 reworded
CRISPR Therapeutics highlights growing dependencies on Vertex for manufacturing CASGEVY and expanding AI integration risks.
Filed Feb 12, 2026 - FY2024 10-K risk factors98 risks
Operating losses will continue despite prior profitability from the Vertex collaboration on CASGEVY. Substantial capital is required to fund gene editing development and commercialization. Reliance on Vertex and other partners creates dependencies on external control and collaboration terms.
Filed Feb 11, 2025